Insmed (INSM) Profit After Tax Growth (5y) (2015 - 2026)
Powered by 
Analysis
Insmed (INSM) Profit After Tax Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.35% |
| Mar 31, 2026 | -12.46% |
| Dec 31, 2025 | -26.30% |
| Sep 30, 2025 | -42.19% |
| Jun 30, 2025 | -39.04% |
| Mar 31, 2025 | -31.04% |
| Dec 31, 2024 | -34.94% |
| Sep 30, 2024 | -29.44% |
| Jun 30, 2024 | -35.30% |
| Mar 31, 2024 | -16.33% |
| Dec 31, 2023 | -15.07% |
| Sep 30, 2023 | -12.73% |
| Jun 30, 2023 | -26.45% |
| Mar 31, 2023 | -18.45% |
| Dec 31, 2022 | -19.30% |
| Sep 30, 2022 | -23.84% |
| Jun 30, 2022 | -16.62% |
| Mar 31, 2022 | -20.69% |
| Dec 31, 2021 | -10.54% |
| Sep 30, 2021 | -24.52% |